[go: up one dir, main page]

AR065688A1 - Conjugados de peptidos antifusogenicos - Google Patents

Conjugados de peptidos antifusogenicos

Info

Publication number
AR065688A1
AR065688A1 ARP080100996A ARP080100996A AR065688A1 AR 065688 A1 AR065688 A1 AR 065688A1 AR P080100996 A ARP080100996 A AR P080100996A AR P080100996 A ARP080100996 A AR P080100996A AR 065688 A1 AR065688 A1 AR 065688A1
Authority
AR
Argentina
Prior art keywords
conjugates
antifusogenic peptides
polypeptide
conjugate
group
Prior art date
Application number
ARP080100996A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of AR065688A1 publication Critical patent/AR065688A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/472—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/15—Retroviridae, e.g. bovine leukaemia virus, feline leukaemia virus human T-cell leukaemia-lymphoma virus
    • C07K14/155—Lentiviridae, e.g. human immunodeficiency virus [HIV], visna-maedi virus or equine infectious anaemia virus
    • C07K14/16—HIV-1 ; HIV-2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • AIDS & HIV (AREA)
  • General Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Un conjugado de polipéptidos, donde el conjugado comprende un primer polipéptido seleccionado del grupo de polipéptidos que comprende SEQ ID N°:1 y fragmentos de éste, y un segundo polipéptido seleccionado del grupo de péptidos antifusogénicos. Sedivulga una composicion farmacéutica que comprende el conjugado de polipéptidos de la presente para la elaboracion de un medicamento para el tratamiento de infecciones víricas tales como HIV.
ARP080100996A 2007-03-13 2008-03-11 Conjugados de peptidos antifusogenicos AR065688A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07005096 2007-03-13

Publications (1)

Publication Number Publication Date
AR065688A1 true AR065688A1 (es) 2009-06-24

Family

ID=37998311

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP080100996A AR065688A1 (es) 2007-03-13 2008-03-11 Conjugados de peptidos antifusogenicos

Country Status (17)

Country Link
US (1) US20090143288A1 (es)
EP (1) EP2118125B1 (es)
JP (1) JP5081931B2 (es)
KR (1) KR101182951B1 (es)
CN (1) CN101616929B (es)
AR (1) AR065688A1 (es)
AT (1) ATE530564T1 (es)
AU (1) AU2008226051B2 (es)
BR (1) BRPI0808732A2 (es)
CA (1) CA2679647A1 (es)
CL (1) CL2008000707A1 (es)
ES (1) ES2374962T3 (es)
IL (1) IL199718A0 (es)
MX (1) MX2009009370A (es)
PE (1) PE20090163A1 (es)
TW (1) TW200902544A (es)
WO (1) WO2008110332A1 (es)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010107825A2 (en) 2009-03-16 2010-09-23 Pangu Biopharma Limited Compositions and methods comprising histidyl-trna synthetase splice variants having non-canonical biological activities
GB0913385D0 (en) 2009-07-31 2009-09-16 Medical House The Plc Improved autoinjector
MX2013002556A (es) * 2010-09-14 2013-05-28 Hoffmann La Roche Polipeptido de fusion de dedo de serpina.
JP6397479B2 (ja) * 2013-03-15 2018-09-26 エータイアー ファーマ， インコーポレイテッド ヒスチジル−ｔＲＮＡシンテターゼＦｃコンジュゲート
ES2978297T3 (es) * 2017-05-17 2024-09-10 Massachusetts Gen Hospital Terapia génica para la esclerosis tuberosa

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
WO1992008796A1 (en) 1990-11-13 1992-05-29 Immunex Corporation Bifunctional selectable fusion genes
WO1992009305A1 (en) 1990-11-27 1992-06-11 Biogen, Inc. Anti cd-4 antibodies blocking hiv-induced syncytia
NZ243706A (en) 1991-07-25 1994-08-26 Idec Pharma Corp Recombinant monkey antibodies, pharmaceutical compositions
US6136310A (en) * 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
ES2139017T3 (es) * 1992-07-20 2000-02-01 Univ Duke Compuestos que inhiben la replicacion del vih.
AU6953394A (en) 1993-05-21 1994-12-20 Targeted Genetics Corporation Bifunctional selectable fusion genes based on the cytosine deaminase (cd) gene
US6479055B1 (en) * 1993-06-07 2002-11-12 Trimeris, Inc. Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
US5464933A (en) 1993-06-07 1995-11-07 Duke University Synthetic peptide inhibitors of HIV transmission
US6017536A (en) * 1993-06-07 2000-01-25 Trimeris, Inc. Simian immunodeficiency virus peptides with antifusogenic and antiviral activities
EP0840618B1 (en) 1995-05-18 2003-04-23 Ortho-McNeil Pharmaceutical, Inc. Induction of immunological tolerance by the use of non-depleting anti-cd4 antibodies
US6743594B1 (en) * 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
US6475491B1 (en) 1995-06-07 2002-11-05 Trimeris, Inc. Treatment of HIV and other viral infections using combinatorial therapy
AU3375697A (en) * 1996-05-28 1998-01-05 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Cc chemokine receptor 5, antibodies thereto, transgenic animals
ATE335835T1 (de) 1996-06-03 2006-09-15 United Biomedical Inc Antikörper gegen einen komplex aus cd4 und einer chemokinrezeptordomäne, sowie deren verwendung gegen hiv infektionen
US6020159A (en) 1996-09-24 2000-02-01 Smithkline Beecham Corporation 3-dehydroquinate synthase
US6528625B1 (en) * 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US5888809A (en) * 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
US6020495A (en) * 1997-12-08 2000-02-01 Pharm-Eco Laboratories, Inc. Stereoselective method for synthesizing dolaphenine
US6656906B1 (en) * 1998-05-20 2003-12-02 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6258782B1 (en) * 1998-05-20 2001-07-10 Trimeris, Inc. Hybrid polypeptides with enhanced pharmacokinetic properties
US6610834B1 (en) * 1998-11-18 2003-08-26 Peter I. Lobo Human IgM antibodies to chemokine receptors
US20030099645A1 (en) * 2000-10-10 2003-05-29 Lobo Peter Isaac Naturally occuring IgM antibodies that bind to membrane receptors on lymphocytes
WO2000035409A2 (en) 1998-12-16 2000-06-22 Progenics Pharmaceuticals, Inc. Hiv-i fusion inhibition compounds
HUP0200484A2 (en) 1999-03-11 2002-06-29 Micromet Ag Antibody and chemokine constructs that are directed to ccr5, and their use for treating autoimmune diseases
ES2334106T3 (es) * 1999-05-17 2010-03-05 Conjuchem Biotechnologies Inc. Inhibidores peptidos de fusion de larga vida contra infecciones virales.
WO2001042308A2 (en) 1999-12-08 2001-06-14 Novartis Ag Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
AU2265701A (en) 1999-12-16 2001-06-25 Tanox, Inc. Anti-hiv-1 conjugates for treatment of hiv disease
US6692745B2 (en) * 2000-01-28 2004-02-17 Arogenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
WO2001058916A2 (en) 2000-02-09 2001-08-16 Human Genome Sciences, Inc. Antibodies to ccr5
US20040043033A1 (en) * 2000-05-01 2004-03-04 Green Lorrence H. Method and vaccine for the prevention of AIDS
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US20030165988A1 (en) * 2002-02-08 2003-09-04 Shaobing Hua High throughput generation of human monoclonal antibody against peptide fragments derived from membrane proteins
US7005503B2 (en) * 2002-02-08 2006-02-28 Genetastix Corporation Human monoclonal antibody against coreceptors for human immunodeficiency virus
EP1207202A1 (en) 2000-11-16 2002-05-22 Mölling, Karin, Inst. für med. Virologie der Uni. Zürich Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US20020147147A1 (en) * 2000-11-16 2002-10-10 Karin Molling Nucleic acid molecules encoding a protein interacting with the chemokine receptor CCR5 or other chemokine receptor family members
US7175988B2 (en) * 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US20030003440A1 (en) * 2001-03-14 2003-01-02 Lucia Lopalco Novel CCR5 epitope and antibodies against it
US20020146415A1 (en) 2001-04-06 2002-10-10 Olson William C. Methods for inhibiting HIV-1 infection
US7060273B2 (en) * 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
KR100614714B1 (ko) * 2001-06-15 2006-08-21 에프. 호프만-라 로슈 아게 ｇｐ41 단편의 아세틸화
EP1450857B1 (en) 2001-10-16 2010-09-15 The Government of the United States of America, represented by The Secretary, Department of Health and Human Services Broadly cross-reactive neutralizing antibodies against human immunodeficiency virus selected by env-cd4-co-receptor complexes
WO2003066830A2 (en) 2002-02-08 2003-08-14 Genetastix Corporation Human monoclonal antibodies against membrane proteins
DK1478738T3 (da) 2002-02-22 2009-03-09 Pdl Biopharma Inc Anti-CCR5-antistof
US7122185B2 (en) * 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
EP1460088A1 (en) * 2003-03-21 2004-09-22 Biotest AG Humanized anti-CD4 antibody with immunosuppressive properties
EP1708734A4 (en) * 2004-01-07 2009-06-17 Trimeris Inc PEPTIDES DERIVED FROM HIV GP41 HR2 AND THEIR USE IN THERAPY TO INHIBIT THE TRANSMISSION OF HUMAN IMMUNODICIENCY VIRUS
TW200720289A (en) 2005-04-01 2007-06-01 Hoffmann La Roche Antibodies against CCR5 and uses thereof

Also Published As

Publication number Publication date
IL199718A0 (en) 2010-04-15
ATE530564T1 (de) 2011-11-15
KR101182951B1 (ko) 2012-09-13
CA2679647A1 (en) 2008-09-18
CL2008000707A1 (es) 2008-09-22
US20090143288A1 (en) 2009-06-04
EP2118125B1 (en) 2011-10-26
AU2008226051B2 (en) 2012-05-24
ES2374962T3 (es) 2012-02-23
BRPI0808732A2 (pt) 2014-08-12
TW200902544A (en) 2009-01-16
MX2009009370A (es) 2009-09-14
CN101616929B (zh) 2013-08-14
AU2008226051A1 (en) 2008-09-18
JP2010520868A (ja) 2010-06-17
EP2118125A1 (en) 2009-11-18
KR20090115867A (ko) 2009-11-09
JP5081931B2 (ja) 2012-11-28
WO2008110332A1 (en) 2008-09-18
PE20090163A1 (es) 2009-03-12
CN101616929A (zh) 2009-12-30

Similar Documents

Publication Publication Date Title
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
BR112012029975A2 (pt) peptídeo como medicamento, em particular para o tratamento do câncer.
EP3058954A3 (en) Immunogenic compositions and methods
EA201790871A1 (ru) Нацеленные конъюгатные композиции xten и способы их получения
PE20230404A1 (es) Un conjugado que comprende oxintomodulina y un fragmento de inmunoglobulina, y uso del mismo
WO2011008348A3 (en) Dual vector for inhibition of human immunodeficiency virus
NZ601818A (en) Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers
CO6531435A2 (es) Nuevas formulaciones de vacuna que comprende adyuvantes que contienen saponina
EP4306538A3 (en) Peptide oligonucleotide conjugates
DE602007011901D1 (de) Ptiden und zellpenetrierenden peptiden gekoppelt a
CY1115841T1 (el) Εμβολια πεπτιδιου παραγομενα απο epha4
WO2009026397A3 (en) Prophylactic and therapeutic influenza vaccines, antigens, compositions, and methods
ES2454773T3 (es) Fragmentos solubles de la proteína PB2 del virus influenza con capacidad para unirse a un casquete de ARN
MX2016002937A (es) Vacuna oncologica.
AR065688A1 (es) Conjugados de peptidos antifusogenicos
AR059300A1 (es) Peptidos inhibidores de la fusion de vih con propiedades biologicas mejoradas
EA201990885A1 (ru) Композиции, содержащие короткие пептиды, полученные из pedf, и их применение
MX2019006943A (es) Polipéptidos para manejo de infecciones virales.
RU2015101081A (ru) Стабилизированный gp120
WO2011053789A3 (en) Pharmaceutical composition and methods to enhance cytotoxic t-cell recognition and maintain t-cell memory against a pathogenic disease
WO2010041241A3 (en) Hiv-1 integrase derived stimulatory peptides interfering with integrase - rev protein binding
UA118542C2 (uk) Імуногенна сполука, що включає пептид gp41 віл, зв'язаний з білком-носієм crm197
CL2021001479A1 (es) Péptido; uso de composiciones; composición farmacéutica; uso de un anticuerpo para terapia; uso de un anticuerpo para elisa, inmunohistoquímica y/o formación de imágenes; receptor de linfocito t; y uso de un linfocito t citotóxico activado (divisional de la solicitud n° 201701391)
AR071125A1 (es) Peptidos muy puenteados a partir de actinomadura namibiensis
JP2013542196A5 (es)

Legal Events

Date Code Title Description
FB Suspension of granting procedure